Innovative therapeutics

Products/
Pipeline

Naglazyme® for MPS VI

Current Clinical Trials: MPS VI

Study: Mucopolysaccharidosis (MPS) VI Clinical Surveillance Program (CSP)

Indication: Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome)

Investigational Therapeutic: Naglazyme

Study Type: Phase 4

Goal: The objectives of this program are: to further characterize the natural progression of MPS VI disease; to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals; to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data; to characterize the clinical response to long-term Naglazyme® (galsulfase) treatment; to further characterize the long-term safety of Naglazyme® treatment.

Status: This study is currently recruiting participants

Additional information: View on Clinicaltrials.gov

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information

Top